AR103832A1 - Formulaciones farmacéuticas de un inhibidor de tirosina quinasa de bruton - Google Patents
Formulaciones farmacéuticas de un inhibidor de tirosina quinasa de brutonInfo
- Publication number
- AR103832A1 AR103832A1 ARP160100550A ARP160100550A AR103832A1 AR 103832 A1 AR103832 A1 AR 103832A1 AR P160100550 A ARP160100550 A AR P160100550A AR P160100550 A ARP160100550 A AR P160100550A AR 103832 A1 AR103832 A1 AR 103832A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- pharmaceutical formulations
- conditions
- bruton
- quinasa
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 229940124291 BTK inhibitor Drugs 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 229940125814 BTK kinase inhibitor Drugs 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000007916 tablet composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000005550 wet granulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formulaciones farmacéuticas del inhibidor de tirosina quinasa de Bruton (Btk) 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona. Métodos para usar el inhibidor de Btk, solo o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluido el linfoma, y enfermedades o condiciones inflamatorias. Reivindicación 52: Un proceso para preparar la formulación de comprimido sólido de alta carga de cualquiera de las reivindicaciones 1 a 49, caracterizado porque el proceso comprende un método de granulación húmeda.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562127717P | 2015-03-03 | 2015-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR103832A1 true AR103832A1 (es) | 2017-06-07 |
Family
ID=59254075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160100550A AR103832A1 (es) | 2015-03-03 | 2016-03-02 | Formulaciones farmacéuticas de un inhibidor de tirosina quinasa de bruton |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR103832A1 (es) |
MA (1) | MA41643B1 (es) |
-
2016
- 2016-03-02 AR ARP160100550A patent/AR103832A1/es unknown
- 2016-03-02 MA MA41643A patent/MA41643B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
MA41643B1 (fr) | 2024-02-29 |
MA41643A (fr) | 2018-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2022000096A (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
MX2021015368A (es) | Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton. | |
MX2017001671A (es) | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. | |
MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
EA201591656A1 (ru) | Комбинированная терапия с ибрутинибом | |
EA201690746A1 (ru) | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии | |
NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
PH12015502053A1 (en) | Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors | |
NZ728392A (en) | High dosage strength tablets of rucaparib | |
MX2017012430A (es) | Formas solvatadas de un inhibidor de tirosina quinasa de bruton. | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
JOP20200231A1 (ar) | ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها | |
UY37559A (es) | Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton | |
WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
BR112018076622A2 (pt) | pirrolo[2,3-d]piridazin-4-onas e pirazolo[3,4-d]piridazin-4-onas substituídas como inibidores de proteína cinase | |
AR103832A1 (es) | Formulaciones farmacéuticas de un inhibidor de tirosina quinasa de bruton | |
TW202419091A (zh) | 布魯東氏(bruton’s)酪胺酸激酶抑制劑之醫藥調配物 | |
TR201711933A2 (tr) | Ti̇rozi̇n ki̇naz 2 (tyk2) enzi̇mi̇ni̇ selekti̇f i̇nhi̇be eden heterosi̇kli̇k bi̇leşi̇kler | |
AR098210A1 (es) | Combinaciones de inhibidores de la tirosina quinasa de bruton e inmunoterapias | |
NZ723518A (en) | Salts and solid form of a btk inhibitor | |
TH168817A (th) | อนุพันธ์อินโดลิซีนซึ่งเป็นสารยับยั้งฟอสโฟอิโนซิไทด์ 3-ไคเนส | |
UY35587A (es) | Método de tratamiento del cáncer |